Xenikos is interested in strategic collaborations to advance its internal development programs with T-Guard® as well as to apply its technologies against novel targets.

Xenikos also seeks clinical and research partners to continue to explore the potential of T-Guard in other geographies and in other indications beyond graft-versus-host disease in which T cells play a crucial role, such as solid organ rejection and severe autoimmune diseases.

In addition, joining forces with organizations and associations and fostering close links with research, industry, healthcare professionals and the medical authorities that shape the healthcare landscape is important to ensure that Xenikos contributes as much as possible to advancing medicine for the benefit of patients.

To find out more about partnership opportunities, please contact Ypke van Oosterhout at info@xenikos.com.